Fenoldopam

Fenoldopam

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Fenoldopam
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Intravenous
ATC code	C01CA19 (WHO)
Pharmacokinetic data
Bioavailability	n/a
Metabolism	Hepatic (CYP not involved)
Elimination half-life	5 minutes
Excretion	Renal (90%) and fecal (10%)
Identifiers
IUPAC name 8-chloro-2-(4-hydroxyphenyl)- 4-azabicyclo[5.4.0] undeca-7,9,11-triene-9,10-diol
CAS Number	67227-57-0
PubChem CID	3341
DrugBank	APRD00969
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H16ClNO3
Molar mass	305.756 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Fenoldopam is a synthetic compound that acts as a selective peripheral dopamine D_1A receptor agonist. Fenoldopam is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation, decreasing afterload and also through specific dopamine receptors along the nephron promoting sodium excretion.